Xilio Therapeutics, Inc.
XLO evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $58.8M
- Lead Asset:
- vilastobart (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for XLO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XLO
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies for cancer, with a focus on next-generation multi-specific T cell engagers and a lead program in Phase 1/2 studies.
Key risk: No commercialized products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Xilio Therapeutics, Inc..
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies for cancer, with a focus on next-generation multi-specific T cell engagers and a lead program in Phase 1/2 studies.
- Cash and cash equivalents of $136.0 million as of June 30, 2026 [sec_mda].
- Total revenue of $18.7M and net income of -$6.4M for the latest reported period as of 2026-06-30 [sec].
- Received FDA clearance of IND application for XTX501, a bispecific PD-1 / masked IL-2 candidate [news].
- Accumulated deficit of $434.7 million as of June 30, 2026 [sec_mda].
- Cash runway expected into the first quarter of 2028, based on current operating plans and a $6.0 million AbbVie milestone [sec_mda].
What works
- Cash runway into Q1 2028 provides financial stability to advance pipeline programs [sec_mda].
- FDA clearance of IND for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, supports pipeline progress [news].
- Collaboration with AbbVie generated a $6.0 million development milestone in Q2 2026 [sec_mda].
- Multiple IND applications anticipated in H2 2027 for first-in-class multi-specific T cell engager programs [news].
What to weigh
- No product candidates have been commercialized; no revenue from product sales expected for several years [sec_mda].
- Accumulated deficit of $434.7 million as of June 30, 2026, reflecting ongoing net losses [sec_mda].
- Net loss of $35.0 million for the year ended December 31, 2025, and continued operating losses expected [sec_mda].
- Cash runway estimate excludes potential additional milestone payments and contingent payments from collaborations [sec_mda].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of June 30, 2026, we had cash and cash equivalents of $136.0 million.”
SEC MD&A · August 12, 2026
FDA clearance for XTX501 IND
“Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2”
News · August 12, 2026
Accumulated deficit
“As of June 30, 2026, we had an accumulated deficit of $434.7 million.”
SEC MD&A · August 12, 2026
Net loss for 2025
“a net loss of $35.0 million for the year ended December 31, 2025.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2022-01-18 · Phase 1/2 study start for XTX202 in advanced solid tumors — First-in-human study of XTX202, a masked IL-12 candidate, initiated.
- 2023-05-11 · Phase 1/2 study start for XTX301 in advanced solid tumors — First-in-human study of XTX301, a masked IL-2 candidate, initiated.
- 2026-08-01 · Phase 1/2 study start for XTX501 in metastatic non-small cell lung cancer and advanced solid tumors — Study of XTX501, a bispecific PD-1 / masked IL-2, initiated following IND clearance.
Risks & what to watch (3)›
Key risks
- No commercialized products — No product candidates have been commercialized; no product revenue expected for several years [sec_mda].
- Accumulated deficit — Accumulated deficit of $434.7 million as of June 30, 2026, with ongoing net losses [sec_mda].
- Cash runway dependency — Cash runway estimate excludes potential additional milestone payments from collaborations [sec_mda].
What to watch
- IND submissions for CLDN18.2 and PSMA+STEAP1 multi-specific T cell engager programs anticipated in H2 2027 [news].
- Phase 1/2 study initiation for XTX501 in metastatic non-small cell lung cancer and advanced solid tumors [catalyst].
- Potential exercise of Series C warrants providing up to $36.2 million in additional gross proceeds [sec_mda].
- Progress of vilastobart (XTX101) Phase 1/2 study in advanced solid tumors [pipeline].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Xilio Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xilio Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.13
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 3.8%
- Days to cover
- 3.8
- Shares short
- 174,319
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XLO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xilio Therapeutics, Inc.?
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies for cancer, with a focus on next-generation multi-specific T cell engagers and a lead program in Phase 1/2 studies.
What is Xilio Therapeutics, Inc.'s lead drug candidate?
Xilio Therapeutics, Inc.'s most advanced tracked candidate is vilastobart (Phase 1/Phase 2) for Advanced Solid Tumor.
Who is the CEO of Xilio Therapeutics, Inc.?
Dr. Rene Russo BCPS, Pharm.D. is the chief executive officer of Xilio Therapeutics, Inc. (XLO).
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. (XLO) is headquartered in Waltham, MA, United States.
What therapeutic areas does Xilio Therapeutics, Inc. focus on?
Xilio Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.